Open Access

SP1 promotes tumor angiogenesis and invasion by activating VEGF expression in an acquired trastuzumab‑resistant ovarian cancer model

  • Authors:
    • Feng Su
    • Jing Geng
    • Xinying Li
    • Chuan Qiao
    • Longlong Luo
    • Jiannan Feng
    • Xinjun Dong
    • Ming Lv
  • View Affiliations

  • Published online on: September 25, 2017     https://doi.org/10.3892/or.2017.5998
  • Pages: 2677-2684
  • Copyright: © Su et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Ovarian cancer is one of the most common gynecologic cancers and the leading cause of mortality in women worldwide. HER2/neu is overexpressed in various types of cancers and is most commonly associated with decreased survival. Trastuzumab is a humanized anti-HER2 monoclonal antibody for the treatment of HER2-positive breast cancers. However, primary and/or acquired resistance occurs in up to 62% patients during the first year of treatment. Vascular endothelial growth factor (VEGF) is a well‑known angiogenesis factor involved in many physiological and pathological processes. Its significance has been implicated in promoting tumor growth and metastasis via angiogenesis. In the present study, we demonstrated that the upregulation of SP1 enhanced expression of VEGF promoting the angiogenesis and migration of trastuzumab-resistant ovarian cancer cell line SKOV3-T. Our in vitro and in vivo results both gave evidence that the SP1-VEGF axis was responsible for the enhanced malignancy, angiogenesis and migration in the acquired trastuzumab-resistant ovarian cancer cell model.
View Figures
View References

Related Articles

Journal Cover

November-2017
Volume 38 Issue 5

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Su F, Geng J, Li X, Qiao C, Luo L, Feng J, Dong X and Lv M: SP1 promotes tumor angiogenesis and invasion by activating VEGF expression in an acquired trastuzumab‑resistant ovarian cancer model. Oncol Rep 38: 2677-2684, 2017
APA
Su, F., Geng, J., Li, X., Qiao, C., Luo, L., Feng, J. ... Lv, M. (2017). SP1 promotes tumor angiogenesis and invasion by activating VEGF expression in an acquired trastuzumab‑resistant ovarian cancer model. Oncology Reports, 38, 2677-2684. https://doi.org/10.3892/or.2017.5998
MLA
Su, F., Geng, J., Li, X., Qiao, C., Luo, L., Feng, J., Dong, X., Lv, M."SP1 promotes tumor angiogenesis and invasion by activating VEGF expression in an acquired trastuzumab‑resistant ovarian cancer model". Oncology Reports 38.5 (2017): 2677-2684.
Chicago
Su, F., Geng, J., Li, X., Qiao, C., Luo, L., Feng, J., Dong, X., Lv, M."SP1 promotes tumor angiogenesis and invasion by activating VEGF expression in an acquired trastuzumab‑resistant ovarian cancer model". Oncology Reports 38, no. 5 (2017): 2677-2684. https://doi.org/10.3892/or.2017.5998